MedTrace Logo

Study of Chronic Rhinosinusitis Symptoms in Asthma Patients Undergoing Treatment With Reslizumab

NCT03369574 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2019-11-13

No results posted yet for this study

Summary

The primary objective of this research is to monitor chronic rhinosinusitis (CRS) symptoms in asthma patients who are undergoing treatment with reslizumab. A secondary objective is to explore whether there are sub-populations that appear to benefit or not benefit from reslizumab in terms of their CRS symptoms.

Conditions

  • Chronic Rhinosinusitis (Diagnosis)
  • Asthma
  • Nasal Polyps

Interventions

DRUG

Reslizumab

reslizumab administration

Sponsors & Collaborators

  • University of Rochester

    lead OTHER

Principal Investigators

  • Li-Xing Man, MSc, MD, MPA · University of Rochester

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-14
Primary Completion
2018-10-19
Completion
2018-10-19
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03369574 on ClinicalTrials.gov